Mont-Saint-Guibert, Belgium, - The Belgian biotechnology company Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris : CARD), leader in the discovery and development of advanced regenerative therapies for heart disease, is pleased to announce that it has been short listed for two 2014 European Mediscience Awards, the “Breakthrough Award” and “The Best Technology Award” .

The European Mediscience Awards is the premier event for all stakeholders of the European mediscience sector and celebrates outstanding achievement of both public and private companies in the healthcare, biotech and life science sectors. 

Cardio3 BioSciences’ most advanced therapy, C-Cure® is being developed as a treatment for heart failure and consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to regenerate the heart. This process is known as Cardiopoiesis. C-Cure® is in a Phase III clinical trial in Europe. The trial, called CHART-1, represents the world’s first Phase III trial for a preprogrammed cellular therapy targeting heart failure. C-Cure® builds on research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre Aalst (Aalst, Belgium).

Dr Christian Homsy, CEO of Cardio3 BioSciences, comments: “We are very proud and honored to have been nominated for two 2014 European Mediscience Awards. We have been developing our breakthrough approach to heart failure for many years with the goal to profoundly improve quality of life for patients and their families. These nominations recognize the progress we have made, together with other players in regenerative medicine, towards inventing a new industry, a new medical approach and in bringing new hope for patients.”

Download press release(s)

Communiqué de presse

110.62 Ko

Press release

101.48 Ko

Cardio3 BioSciences Receives Authorization to Enroll Patients in Sweden in its Phase III C...

Next News

Cardio3 BioSciences Receives Authorization to Enroll Patients in Sweden in its Phase III C...